Home > Insider Trading > Filing (0001104659-20-083172)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1280600	Acceleron Pharma Inc	XLRN	Pharmaceutical Preparations (2834)	DE

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
14272	Bristol Myers Squibb Co	430 E. 29Th Street 14 Floor New York NY 10016		No	No	Yes	No
816284	Celgene Corp /De/	86 Morris Avenue Summit NJ 07901		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-09	38,979	$5.88	7,010,751	No	4	X	Direct
Common Stock	Disposition	2020-07-09	2,241	$102.28	7,008,510	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	X	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, $0.001 Par Value	Option Warrant	Disposition	2020-07-09	38,979	$0.00	38,979	$5.88

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2020-07-09	No	4	X	Direct

Footnotes

This statement is being filed jointly by Celgene Corporation and Bristol-Myers Squibb Company (the "Reporting Persons").
These shares are owned directly by Celgene Corporation, which is a wholly owned subsidiary of Bristol-Myers Squibb Company. Bristol-Myers Squibb Company is an indirect beneficial owner of the reported securities.
On July 9, 2020, the Reporting Persons exercised a warrant to purchase 38,979 shares of the Issuer's common stock for $5.88 per share. The Reporting Persons paid the exercise price on a cashless basis, resulting in the Issuer withholding 2,241 of the warrant shares to pay the exercise price and issuing to the Reporting Persons the remaining 36,738 shares.
All of the shares are currently exercisable.